In a statement to CBS News about this lawsuit and others against it, Novo Nordisk said in part, "The known risks and benefits of semaglutide and liraglutide medicines are described in their FDA-approved product labeling." The company wrote that "the allegations in the lawsuits are without merit" and said it intends to "vigorously defend against these claims." Novo Nordisk also said semaglutide, the drug sold under the Ozempic and Wegovy brand names, has been extensively examined in robust clinical development programs and large real world evidence studies
For fatigue and low energy If GLP-1 fatigue is dragging you down, your smoothie strategy shifts
For Memory Support: Acetyl L-Carnitine is an excellent nootropic
A big question clinicians will likely hear is whether someone needs to stop taking Ozempic, Wegovy, or Zepbound once they get pregnant
However, compared to small molecule inhibitors, the discovery of small molecule activators is much more challenging ( ex vivo assays
Hunger accompanied by hypoglycemic symptoms requires immediate attention, particularly in patients taking Zepbound alongside other diabetes medications
